Zymeworks (ZYME) Non Operating Income (2021 - 2026)
Zymeworks (ZYME) posted Non Operating Income of $120000.0 for Q1 2026, down 99.12% sequentially from $13.6 million in Q4 2025, and down 96.5% YoY from $3.4 million in Q1 2025.
Powered by 
Analysis
Zymeworks (ZYME) Non Operating Income (2021 - 2026) Analysis & Trends
Zymeworks has reported Non Operating Income for 6 years, with the latest figure at $120000.0 in Q1 2026.
- Quarterly Non Operating Income fell 96.5% year-over-year to $120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.4 million (down 41.78% YoY) and the FY2025 annual result came in at $13.4 million, down 33.03% from the prior year.
- Non Operating Income declined to $120000.0 in Q1 2026 per ZYME's latest filing, from $13.6 million in the prior quarter.
- Over five years, Non Operating Income peaked at $19.8 million in Q4 2023 and troughed at -$692000.0 in Q4 2022.
- A 5-year average of $3.6 million and a median of $304000.0 in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 2956.5% in 2023, then sank 644.74% in 2025.
- Over 5 years, Non Operating Income stood at -$692000.0 in 2022, then surged by 2956.5% to $19.8 million in 2023, then dropped by 0.2% to $19.7 million in 2024, then plunged by 31.0% to $13.6 million in 2025, then slumped by 99.12% to $120000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $120000.0, $13.6 million, and $315000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Zymeworks | 2.14 Bn | 1.87 Bn | - | 196,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 196,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | -302,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | -621,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 344,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Jun 30, 2024 | 114,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Dec 31, 2023 | -832,000.00 |
| Sep 30, 2023 | 634,000.00 |
| Jun 30, 2023 | -209,000.00 |
| Mar 31, 2023 | -487,000.00 |
| Dec 31, 2022 | -692,000.00 |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 759,000.00 |
| Mar 31, 2022 | -315,000.00 |
| Dec 31, 2021 | -1.64 Mn |
| Sep 30, 2021 | 1.15 Mn |